We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Immunoprofiling HTLV-1 Blood Samples Show Altered Innate Cell Responsiveness

By LabMedica International staff writers
Posted on 09 Dec 2021
Print article
Image: The BD LSRFortessa X-20 Cell Analyzer can be configured with up to five lasers to detect up to 20 parameters simultaneously to support ever increasing demands in multicolor flow cytometry (Photo courtesy of BD Bioscience)
Image: The BD LSRFortessa X-20 Cell Analyzer can be configured with up to five lasers to detect up to 20 parameters simultaneously to support ever increasing demands in multicolor flow cytometry (Photo courtesy of BD Bioscience)
The Human T-cell Leukemia Virus-1 (HTLV-1)-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP) is a progressive neurodegenerative disease characterized by the demyelination of the middle-to-lower thoracic cord.

HTLV-1 targets mainly T-cells, altering their function and ability to induce an antiviral specific immune response, even participating in the disease evolution as mentioned previously. However, in addition to T-cells, HTLV-1 also targets innate immune cells such as classical and plasmacytoid dendritic cells (cDCs and pDCs, respectively), as well as monocytes.

Medical Virologists at the Université Claude Bernard Lyon 1 (Lyon, France) and their colleagues analyzed innate cell responses at steady state and after blood cell stimulation using an agonist of the toll-like receptor (TLR)7/8-signaling pathway in blood samples from a Brazilian cohort (15 HAM/TSP patients, 15 HTLV-1 asymptomatic carriers, and 15 non-infected individuals). The average age was 52 ±6.35 years for men and 49.15 ±10.84 years for women. Age means were 49.8 years for healthy donors (HD), 46.93 years for asymptomatic carriers (AC) and 53.8 years for HAM/TSP.

HTLV-1 serologic diagnosis was made by ELISA (Ortho Diagnostics, Rochester, NY, USA) and positive samples were confirmed by western blot. All patients whose serum sample was reactive with either test was submitted to a nested-PCR using HTLV-1 generic primers and amplified products were digested with restriction enzymes. Blood samples were processed, stimulated and analyzed with a LSR Fortessa X-20 cytometer (BD Biosciences, San Jose, CA, USA). Fluorochrome compensation was performed with BD Biosciences’ compensation beads and FMO (Fluorescence Minus One) conditions.

The investigators observed a lower response of IFNα+ DCs and monocytes in HAM/TSP compared to asymptomatic carriers, as a potential consequence of corticosteroid treatments. In contrast, a higher frequency of monocytes producing MIP-1α and pDC producing IL-12 was detected in HAM/TSP blood samples, together with higher IFNγ responsiveness of NK cells, suggesting an increase sensitivity to inflammatory response in HAM/TSP patients compared to asymptomatic carriers. This sustained inflammatory responsiveness could be linked or be at the origin of the neuroinflammatory status in HAM/TSP patients.

The authors concluded that their findings suggest an impaired antiviral response and increased inflammatory responsiveness by dendritic cells and monocytes in HAM/TSP patients compared to asymptomatic carriers. This sustained inflammatory responsiveness upon innate cell activation could participate in the establishment of the HAM/TSP disease. The study was published on November 12, 2021 in the journal PLOS Neglected Tropical Diseases.

Related Links:
Université Claude Bernard Lyon 1
Ortho Diagnostics
BD Bioscience


New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Chlamydia Trachomatis Assay
Chlamydia Trachomatis IgG
New
Ultrasonic Cleaner
UC 300 Series

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.